Advance Study

The Memory Disorders Center and Clinical Research Center at Hawaii Pacific Neuroscience became one of top 30 dementia clinics in the US awarded the ADVANCE (Addressing Dementia Via Agitation-Centered Evaluation) research study.

This is a Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer’s Type. Study participants will receive the study drug (AXS-05), an active control (bupropion), or a placebo control (inactive substance) orally as a tablet taken twice daily for five consecutive weeks. Study participants will also receive study-related medical exams and laboratory tests at no cost. Compensation for time and travel may also be available.

Eligible participants:
65-90 years old
Has Alzheimer’s Dementia
Has Agitation due to Alzheimer’s

Call today (808) 564-6113 or Study@HawaiiNeuroscience.com or NIH Clinical Trial Info.
Please share with friends and family who may benefit from the information.